Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

NHS Instructed To Plan For Up To 65,000 Swine Flu Deaths, UK
In a week that has seen the British swine flu death toll reach 29 and it is estimated that 55,000 people have caught the virus, hospitalizing 652 of them, the
generic viagra online
New Study Highlights Threat Of Resistance To Artemisinin-Based Anti-Malarial Drugs
Malaria parasites in western Cambodia have become resistant to artemisinin-based therapies, the first-line treatment for malaria, according to a study published in the New England Journal of Medicine. Resistance to the drugs makes them less effective and could eventually render them obsolete, putting millions of lives at risk.
News of the day
HIV Transmission Safely Reduced In Babies, Mothers By ART Therapy
Giving daily antiretroviral syrup to breastfeeding infants or treating their HIV-infected mothers with highly active antiretroviral drugs is safe and effective in preventing mother-to-child HIV transmission through breast milk, a study led by University of North Carolina at Chapel Hill investigators has found.
Public Health

Sancuso(R) Clinical Trial Application Filed In China

Solasia Pharma K.K., a developer of Western oncology pharmaceuticals in-licensed for commercialization in Asian markets, announced today the filing of clinical trial application (CTA) of SP-01 (long-acting transdermal granisetron patch; brand name: Sancuso®) to the China State Food and Drug Administration (SFDA). This represents the first regulatory-related filing in China made by Solasia. Upon SFDA approval of the application expected in the 1st quarter of 2010, Solasia will initiate Sancuso clinical trials in China through Excel PharmaStudies Inc. (http://www.excel-china.com), China"s largest Clinical Research Organization (CRO). Sancuso is the first and only commercialized long-acting granisetron transdermal product. By releasing the anti-emetic agent granisetron over a 5-day period, Sancuso reduces the need for daily dosing of injectable and oral agents. In China, Sancuso is expected to be well accepted by physicians and nurses seeking a more convenient method to prevent the debilitating effects of nausea and vomiting in patients receiving chemotherapy. As a single application provides protection over 5 days, Sancuso is expected to help reduce the duration of hospital stays of cancer patients currently receiving short-acting anti-emetic agents. About Sancuso Sancuso is a long-acting transdermal system, delivering the anti-emetic, granisetron, steadily into the patient"s bloodstream over seven days without the need for injections or swallowing pills. Granisetron is a 5-HT3 receptor antagonist with well-established efficacy against chemotherapy-induced nausea and vomiting (CINV). Sancuso was approved by the U.S. Food & Drug Administration (FDA) on September 12, 2008. Prostrakan launched Sancuso in the U.S. in the fourth quarter of 2008. Patents protecting Sancuso have been granted in the EU (2007) and Japan (2008). Solasia Pharma K.K.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009